July 2011
Smart Business Northern California;Jul2011, Vol. 4 Issue 8, ps16
The article profiles Dr. N. Anthony Coles, president and chief executive officer (CEO) at Onyx Pharmaceuticals Inc. and a finalist of the Ernst & Young Entrepreneur of the Year Award in the life sciences category in Northern California.


Related Articles

  • Precious Mettle. Comer, Benjamin // Pharmaceutical Executive;Jul2011, Vol. 31 Issue 7, p28 

    The article highlights the role of Tony Coles as chief executive officer (CEO) at Onyx Pharmaceuticals Inc. in leading the company to greater heights in the U.S. It recounts how the condition of his son having a compromising mediastinal mass has influenced his craft in discovering new compounds,...

  • Cell Therapeutics Lands Sweet Deal for JAK Drug. Boggs, Jennifer // BioWorld Today;4/20/2012, Vol. 23 Issue 77, p1 

    The article reports that Cell Therapeutics Inc. has acquired worldwide rights to Phase III-ready JAK2 inhibitor pacritinib from S*Bio Pte Ltd. for an upfront payment of 30 million U.S. dollars. In 2009, Onyx Pharmaceuticals has invested in the JAK program, but it let the program go in 2010 after...

  • Onyx Signs a 10-Year Lease for New MOB. Carr, Robert // National Real Estate Investor Exclusive Insight;3/4/2013, p7 

    The article reports that Onyx Pharmaceuticals Inc. has signed a 10-year lease for single tenant, ground-up development in San Francisco, California.

  • EARNINGS ROUNDUP.  // BioWorld Today;5/6/2010, Vol. 21 Issue 87, p10 

    This article reports on the global net sales of cancer drug Nexavar from Onyx Pharmaceuticals Inc. in the first quarter of 2010.

  • Earnings Roundup.  // BioWorld Today;8/3/2012, Vol. 23 Issue 150, p5 

    The article reports on the 72.7 million dollar revenue from net sales of cancer drug Nexavar posted by Onyx Pharmaceuticals Inc. in the second quarter of 2012.

  • Earnings Roundup.  // BioWorld Today;8/5/2011, Vol. 22 Issue 151, p4 

    The article reports on the non-Generally Accepted Accounting Principles (GAAP) losses posted by Onyx Pharmaceuticals Inc. during the second quarter of 2011.

  • Earnings Roundup.  // BioWorld Today;11/4/2011, Vol. 22 Issue 215, p7 

    The article reports on the financial performance of Onyx Pharmaceuticals of South San Francisco for the third quarter of 2011.

  • Coles is new COO, president of NPS Pharmaceuticals.  // Enterprise/Salt Lake City;11/7/2005, Vol. 35 Issue 19, p4 

    Reports on the appointment of N. Anthony Coles as president and COO of NPS Pharmaceuticals based in Salt Lake City, Utah. Occupational achievement of Coles; Operation of the company.

  • Clinic Roundup.  // BioWorld Today;2/24/2012, Vol. 23 Issue 37, p10 

    This section offers news briefs on clinical trials including the enrollment completed by Onyx Pharmaceuticals Inc. in a trial of carfilzomib for relapsed multiple myeloma, number of trial sites opened by Northwest Biotherapeutics in the U.S. for a study of DCVax-L immune therapy in glioblastoma...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics